文献速递糖尿病

2型糖尿病患者启动肠促胰素类药物后急性胰腺炎与胆道事件风险

Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

本研究基于美国医保与商业理赔数据库(2014-2021),构建三个倾向评分加权队列,比较GLP-1受体激动剂、DPP-4抑制剂与SGLT2抑制剂启动者发生急性胰腺炎(AP)及胆道事件的风险。结果显示GLP-1RA与DPP-4i相比SGLT2i不增加AP风险,但胆道疾病风险轻度升高;GLP-1RA与DPP-4i之间无差异。

要点

  • GLP-1RA与DPP-4i启动者相比SGLT2i启动者,AP住院风险无显著差异。
  • GLP-1RA与DPP-4i启动者相比SGLT2i,胆道疾病风险轻度升高,绝对风险增加小于1例/1000人年。
  • GLP-1RA与DPP-4i之间AP和胆道疾病风险均无差异。

核心结论

  • 在T2D患者中,GLP-1RA和DPP-4i相比SGLT2i与胆道疾病风险轻度增加相关,但不增加AP风险。
  • GLP-1RA与DPP-4i在AP和胆道疾病风险上无差异。

研究设计与样本

  • 基于Medicare FFS和两个美国商业理赔数据库(2014-2021)的回顾性队列研究。
  • 采用倾向评分细分层加权,纳入≥18岁(Medicare FFS中≥65岁)无既往AP或胆道疾病的T2D患者,构建三个两两比较队列。

主要发现

  • GLP-1RA与SGLT2i比较,AP住院的加权HR为1.01(95%CI 0.90-1.13)。
  • DPP-4i与SGLT2i比较,AP住院的加权HR为1.00(95%CI 0.85-1.15)。
  • GLP-1RA与SGLT2i比较,胆道疾病的加权HR为1.15(95%CI 1.05-1.26)。
  • DPP-4i与SGLT2i比较,胆道疾病的加权HR为1.22(95%CI 1.03-1.46),绝对风险增加小于1例/1000人年。
  • GLP-1RA与DPP-4i比较,AP的HR为1.08(95%CI 0.95-1.22),胆道疾病的HR为0.95(95%CI 0.86-1.04)。

临床怎么用

  • 对T2D患者选择肠促胰素类药物时,无需过度担忧AP风险增加。
  • 对于有胆道疾病风险的患者,处方GLP-1RA或DPP-4i时应权衡轻度升高的胆道事件风险。

局限性

  • 观察性研究设计可能残留混杂。
  • 仅纳入美国理赔数据库人群,外推需谨慎。
  • 胆道事件绝对风险增加很小,临床意义有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the association between incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is), and these outcomes. We examined the association between incretin medication use and risk of incident AP or biliary disease in patients with T2D. RESEARCH DESIGN AND METHODS: Using Medicare Fee-for-Service (FFS) and two U.S. commercial claims databases (2014-2021), we identified three pairwise cohorts of propensity score (PS)-based fine stratification-weighted patients aged ≥18 years (≥65 years in Medicare FFS) with T2D without prior AP or biliary disease who initiated treatment with GLP-1RAs versus sodium-glucose cotransporter 2 inhibitors (SGLT2is), DPP-4is versus SGLT2is, or GLP-1RAs versus DPP-4is. PS was estimated using 92 covariates. Weighted hazard ratios (HRs) with 95% CIs for hospitalization because of AP and biliary events were estimated using Cox models. RESULTS: Each cohort included >1.2 million patients. After weighting, GLP-1RA and DPP-4i initiators had similar risk of AP compared with SGLT2i initiators (HR 1.01; 95% CI 0.90-1.13 and HR 1.00; 95% CI 0.85-1.15, respectively). However, both GLP-1RA and DPP-4i initiators showed a modestly increased risk of biliary disease compared with SGLT2i initiators (HR 1.15; 95% CI 1.05-1.26 and HR 1.22; 95% CI 1.03-1.46, respectively), equivalent to fewer than one additional event per 1,000 person-years. There was no difference in risk of AP (HR 1.08; 95% CI 0.95-1.22) or biliary disease (HR 0.95; 95% CI 0.86-1.04) between GLP-1RAs and DPP-4is. CONCLUSIONS: In patients with T2D, GLP-1RAs and DPP-4is were associated with a small increase in risk of biliary disease, but not of AP, compared with SGLT2is.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Fang YE, Paik JM, Ortega-Montiel J, et al. Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes. Diabetes Care. 2025. PMID: 41144235. doi:10.2337/dc25-1840

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。